Patterns of cutaneous immune-related adverse events in adults and children with advanced sarcoma: a retrospective cohort study.

Immune checkpoint inhibitors (ICIs) have improved survival for multiple malignancies in adults and children.1,2 However, their benefits are tempered by a range of serious immune-related adverse events (irAEs). 1,2 Among these, cutaneous irAEs (cirAEs) represent one of the most common subtypes, impacting approximately one-third of adult patients receiving ICIs.1,3 The patterns and significance of cirAEs in children remain unclear, largely because these reactions have not been evaluated in detail.